Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.020 GeneticVariation disease BEFREE Although a minor contribution of SLC6A4 variants in the genetic liability of MOH cannot be excluded, haplotype-based analysis of STin2 VNTR and rs1042173T>G polymorphisms allowed to identify a subgroup of MOH patients with a higher number of monthly headache and, possibly, with a more severe disease. 21585624 2012
Entrez Id: 110806307
Gene Symbol: STIN2-VNTR
STIN2-VNTR
0.020 GeneticVariation disease BEFREE Although a minor contribution of SLC6A4 variants in the genetic liability of MOH cannot be excluded, haplotype-based analysis of STin2 VNTR and rs1042173T>G polymorphisms allowed to identify a subgroup of MOH patients with a higher number of monthly headache and, possibly, with a more severe disease. 21585624 2012
Entrez Id: 796
Gene Symbol: CALCA
CALCA
0.040 Biomarker disease BEFREE Areas covered: This review considers the adverse (or potential) side effects produced by current and prospective antimigraine drugs, including medication overuse headache (MOH) produced by ergots and triptans, the side effects observed in clinical trials for the new gepants and CGRP antibodies, and a section discussing the potential effects resulting from disruption of the cardiovascular CGRPergic neurotransmission. 29226741 2018
Entrez Id: 6283
Gene Symbol: S100A12
S100A12
0.030 Biomarker disease BEFREE Areas covered: This review considers the adverse (or potential) side effects produced by current and prospective antimigraine drugs, including medication overuse headache (MOH) produced by ergots and triptans, the side effects observed in clinical trials for the new gepants and CGRP antibodies, and a section discussing the potential effects resulting from disruption of the cardiovascular CGRPergic neurotransmission. 29226741 2018
Entrez Id: 4524
Gene Symbol: MTHFR
MTHFR
0.010 GeneticVariation disease BEFREE By multivariate logistic stepwise regression analysis, type of migraine, regular and sufficient dietary intake, and methylenetetrahydrofolate reductase (MTHFR) C677T (rs1801133) and dopamine D2 receptor (DRD2) rs6275" genes_norm="1813">C939T (rs6275) polymorphisms were selected as significant factors that contribute independently to the development from migraine to MOH (P < 0.05). 22290307 2013
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.020 GeneticVariation disease BEFREE By multivariate logistic stepwise regression analysis, type of migraine, regular and sufficient dietary intake, and methylenetetrahydrofolate reductase (MTHFR) C677T (rs1801133) and dopamine D2 receptor (DRD2) rs6275" genes_norm="1813">C939T (rs6275) polymorphisms were selected as significant factors that contribute independently to the development from migraine to MOH (P < 0.05). 22290307 2013
Entrez Id: 11280
Gene Symbol: SCN11A
SCN11A
0.010 GeneticVariation disease BEFREE Deletion of the Scn11a gene in MOH mice abrogates NO-mediated symptoms, including cephalic and extracephalic allodynia, photophobia and phonophobia. 31534133 2019
Entrez Id: 29108
Gene Symbol: PYCARD
PYCARD
0.010 Biomarker disease BEFREE Dramatic placebo effect of high frequency repetitive TMS in treatment of chronic migraine and medication overuse headache. 30316627 2019
Entrez Id: 7298
Gene Symbol: TYMS
TYMS
0.010 Biomarker disease BEFREE Dramatic placebo effect of high frequency repetitive TMS in treatment of chronic migraine and medication overuse headache. 30316627 2019
Entrez Id: 6433
Gene Symbol: SFSWAP
SFSWAP
0.010 GeneticVariation disease BEFREE Eighty-eight MOH patients have been compared with two clinical populations including 99 patients with substance use disorder (SUD) and 91 with PDs using the Shedler-Westen Assessment Procedure-200 (SWAP-200), a clinician-report tool that assesses both normal and pathological personality. 31281555 2019
Entrez Id: 50618
Gene Symbol: ITSN2
ITSN2
0.010 GeneticVariation disease BEFREE Eighty-eight MOH patients have been compared with two clinical populations including 99 patients with substance use disorder (SUD) and 91 with PDs using the Shedler-Westen Assessment Procedure-200 (SWAP-200), a clinician-report tool that assesses both normal and pathological personality. 31281555 2019
Entrez Id: 1312
Gene Symbol: COMT
COMT
0.010 GeneticVariation disease BEFREE Functional polymorphisms in COMT and SLC6A4 genes influence the prognosis of patients with medication overuse headache after withdrawal therapy. 24684248 2014
Entrez Id: 5009
Gene Symbol: OTC
OTC
0.010 Biomarker disease BEFREE Groups with high prevalence of MOH should be the focus of public health interventions on rational use of OTC and prescription pain medications. 31522547 2020
Entrez Id: 3355
Gene Symbol: HTR1F
HTR1F
0.010 GeneticVariation disease BEFREE In conclusion, our studydoes not provide evidence that the 5HTT, 5-HT1A, 5HT1B,5HT2A and 5HT6 gene polymorphisms play a role in the genetic predisposition to MOH. 19936617 2010
Entrez Id: 3350
Gene Symbol: HTR1A
HTR1A
0.010 GeneticVariation disease BEFREE In conclusion, our studydoes not provide evidence that the 5HTT, 5-HT1A, 5HT1B,5HT2A and 5HT6 gene polymorphisms play a role in the genetic predisposition to MOH. 19936617 2010
Entrez Id: 5368
Gene Symbol: PNOC
PNOC
0.010 AlteredExpression disease BEFREE In contrast to previous findings in migraine patients, we found normal serum levels of nociceptin and CGRP in MOH patients. 30457160 2019
Entrez Id: 6506
Gene Symbol: SLC1A2
SLC1A2
0.010 Biomarker disease BEFREE In the present study, we aimed to evaluate the role of 14 polymorphisms in 8 candidate genes potentially relevant for drug addiction (OPRM1, DRD2, DBH, COMT, BDNF, SLC6A4, 5HT2A, and SLC1A2) as predictors for detoxification outcome of MOH patients at 2 months of follow-up. 25096645 2014
Entrez Id: 8841
Gene Symbol: HDAC3
HDAC3
0.010 GeneticVariation disease BEFREE In this association study, we sequenced all exons, intron/exon junctions, and 3'-5'UTR regions of HDAC3 in 23 MOH patients to investigate its role in medication overuse. 26542778 2015
Entrez Id: 796
Gene Symbol: CALCA
CALCA
0.040 AlteredExpression disease BEFREE Methods Following sumatriptan priming to model MOH, rats were hyper-responsive to environmental stress, demonstrating delayed cephalic and extracephalic allodynia and increased levels of CGRP in the jugular blood, consistent with commonly observed clinical outcomes during migraine. 28376659 2017
Entrez Id: 6283
Gene Symbol: S100A12
S100A12
0.030 AlteredExpression disease BEFREE Methods Following sumatriptan priming to model MOH, rats were hyper-responsive to environmental stress, demonstrating delayed cephalic and extracephalic allodynia and increased levels of CGRP in the jugular blood, consistent with commonly observed clinical outcomes during migraine. 28376659 2017
Entrez Id: 796
Gene Symbol: CALCA
CALCA
0.040 Biomarker disease BEFREE Objective The objective of this study was the determination of the role of calcitonin gene-related peptide (CGRP) in the induction of medication overuse headache (MOH)-related migraine in an injury-free preclinical model. 27206958 2017
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.020 GeneticVariation disease BEFREE Our results indicate that genotyping for COMT rs4680 and SLC6A4 STin2 VNTR could be useful for the identification of MOH patients at higher risk of poor prognosis after drug withdrawal. 24684248 2014
Entrez Id: 110806307
Gene Symbol: STIN2-VNTR
STIN2-VNTR
0.020 GeneticVariation disease BEFREE Our results indicate that genotyping for COMT rs4680 and SLC6A4 STin2 VNTR could be useful for the identification of MOH patients at higher risk of poor prognosis after drug withdrawal. 24684248 2014
Entrez Id: 796
Gene Symbol: CALCA
CALCA
0.040 Biomarker disease BEFREE Since lasmiditan is a 5-HT<sub>1F</sub> receptor agonist and gepants are CGRP receptor antagonists, they could have different risks for developing MOH because of the different (over) compensation mechanisms following prolonged agonist versus antagonist treatment. 31096904 2019
Entrez Id: 6283
Gene Symbol: S100A12
S100A12
0.030 Biomarker disease BEFREE Since lasmiditan is a 5-HT<sub>1F</sub> receptor agonist and gepants are CGRP receptor antagonists, they could have different risks for developing MOH because of the different (over) compensation mechanisms following prolonged agonist versus antagonist treatment. 31096904 2019